Ther-Biotic ABx Support: CFU, Strain Gaps & AGA Context

Ther-Biotic ABx Support is an antibiotic-period probiotic from SFI Health’s Ther-Biotic line, historically associated with Klaire Labs. It combines a yeast probiotic with three bacterial species for 10 billion CFU per capsule.

The current label identifies the organisms at the species level but does not provide strain codes.

What is in one capsule?

The current SFI product page lists:

• Saccharomyces boulardii — 5 billion CFU;
• Lactobacillus rhamnosus — 2.5 billion CFU;
• Bifidobacterium bifidum — 1.25 billion CFU;
• Bifidobacterium breve — 1.25 billion CFU.

The organisms are carried in an inulin base, but a separate gram amount of inulin is not disclosed.

How it maps to professional guidance

The American Gastroenterological Association suggests several specific probiotic formulations for prevention of C. difficile infection in adults and children receiving antibiotics. The named options include S. boulardii and several explicitly defined bacterial combinations.

Ther-Biotic ABx Support is not an exact formulation match to those named bacterial combinations, and the current label does not provide strain codes for its organisms.

Its intended use overlaps with a clinical scenario in which some probiotics have guideline support, but the product name and species list do not establish equivalent evidence for this exact blend.

Species names do not establish strain equivalence

Two products can both contain L. rhamnosus and still be different research interventions. Evidence from a trial of LGG, for example, should not be assigned to a product that lists only the species.

The same rule applies to S. boulardii. Evidence tied to a named strain such as CNCM I-745 should remain strain-specific unless equivalence is documented.

Practitioner use is a separate evidence category

Practitioner preference, individual tolerability and use within a broader care plan can explain why a formula is selected in practice. Those factors do not substitute for a randomized trial of the finished retail blend.

Safety

People with severe illness, major immune compromise or central venous catheters need medical review before taking live probiotics, particularly products containing live yeast. Significant antibiotic-associated diarrhea, fever, blood in stool, dehydration or suspected C. difficile requires medical evaluation rather than supplement-only management.

Main tradeoff

The label provides a clear CFU breakdown by organism, but not strain designations. No qualifying randomized trial of this exact retail blend was identified in the sources reviewed.

For clearer strain-level traceability, compare Florastor Dual Action or Bio-K+ Advanced Bowel Support.